Psychopharmacology

, Volume 101, Issue 1, pp 142–145 | Cite as

Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers

  • Roger D. Spealman
Rapid Communication

Abstract

The cocaine-antagonist effects of SCH 39166, which selectively blocks D1 dopamine receptors, were compared with those of YM 09151-2, a selective D2 receptor blocker, and flupenthixol, a nonselective blocker of both dopamine receptor subtypes. Squirrel monkeys were studied under a fixed-interval schedule of stimulus-shock termination, and the effects of cumulative doses of cocaine were determined alone and after pretreatment with each dopamine receptor blocker. When administered alone, cocaine (0.01–1.78 mg/kg, IV) had biphasic effects on responding: intermediate doses increased response rate, whereas higher doses decreased response rate. The ED50 for cocaine (average does that produced a half-maximal increase in response rate) was 0.04 mg/kg. Pretreatment with SCH 39166 (0.03 and 0.1 mg/kg, IV) resulted in surmountable antagonism of both the rate-increasing and rate-decreasing effects of cocaine, the ED50 being increased by as much as 13-fold. Similar effects were observed after pretreatment with YM 09151-2 (0.001 and 0.003 mg/kg, IV) and flupenthixol (0.01 and 0.03 mg/kg, IV), which respectively produced up to a 13-fold and 32-fold increase in ED50. There also was evidence for reciprocal antagonism of the rate-decreasing effects of the three dopamine receptor blockers by cocaine. The results suggest a prominent role for D1 as well as D2 dopamine receptors in mediating the effects of cocaine on schedule-controlled behavior.

Key words

Cocaine Behavioral effects Antagonism Dopamine receptors Squirrel monkeys 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barnett A, Iorio LC, Billard W (1986) Relationship of the behavioral effects of SCH 23390 and related benzazepines to their effects on dopamine1 (D1) receptors. In: Biggio G, Spano PF, Gessa GL (eds) Modulation of central and peripheral neurotransmitter function. Liviana Press, Padova, Italy, pp 15–25Google Scholar
  2. Barrett RL, Appel JB (1989) Effects of stimulation and blockade of dopamine receptor subtypes on the discriminative stimulus properties of cocaine. Psychopharmacology 99:13–16Google Scholar
  3. Bergman J, Spealman RD (1988) Behavioral effects of histamine H1 antagonists: comparison with other drugs and modification by haloperidol. J Pharmacol Exp Ther 245:471–478PubMedGoogle Scholar
  4. Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102PubMedGoogle Scholar
  5. Hanson HM, Witoslawski JJ, Campbell EH, Itkin AG (1966) Estimation of relative antiavoidance activity of depressant drugs in squirrel monkeys. Arch Int Pharmacodyn Ther 161:7–16PubMedGoogle Scholar
  6. Herd JA, Morse WH, Kelleher RT, Jones LG (1969) Arterial hypertension in the squirrel monkey during behavioral experiments. Am J Physiol 27:24–29Google Scholar
  7. Herling S, Woods JH (1980) Chlorpromazine effects on cocaine-reinforced responding in rhesus monkeys: reciprocal modification of rate-altering effects of the drugs. J Pharmacol Exp Ther 214:354–361PubMedGoogle Scholar
  8. Hyttel J (1983) SCH 23390 — the first selective dopamine D1 antagonist. Eur J Pharmacol 91:153–154CrossRefPubMedGoogle Scholar
  9. Kleven MS, Anthony EW, Goldberg LI, Woolverton WL (1988) Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonist SCH 23390. Psychopharmacology 95:427–429Google Scholar
  10. Koob GF, Le HT, Creese I (1987) D-1 receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 79:315–321CrossRefPubMedGoogle Scholar
  11. Møller-Nielson I, Pederson V, Nymark M, Franck KF, Boeck V, Fjalland B, Christensen AV (1973) The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacol Toxicol 33:353–362Google Scholar
  12. Scheel-Krüger J, Braestrup C, Nielson M, Golembiowska K, Mogilnicka E (1977) Cocaine: discussion of the role of dopamine in the biochemical mechanism of action. In: Ellinwood EJ, Kilbey MM (eds) Cocaine and other stimulants. Plenum Press, New York, pp 373–407Google Scholar
  13. Spealman RD, Goldberg SR, Kelleher RT, Goldberg DM, Charlton JP (1977) Some effects of cocaine and two cocaine analogs on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 202:500–509PubMedGoogle Scholar
  14. Spealman RD, Bergman J, Madras BK (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142–149PubMedGoogle Scholar
  15. Woolverton WL (1986) Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 24:531–535CrossRefPubMedGoogle Scholar
  16. Woolverton WL, Kleven MS (1988) Multiple dopamine receptors and the behavioral effects of cocaine. In: Clouet D, Asghar K, Brown R (eds) Mechanisms of cocaine abuse and toxicity. NIDA research monograph 88. US Government Printing Office, Washington DC, pp 160–184Google Scholar
  17. Woolverton WL, Virus RM (1989) The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Pharmacol Biochem Behav 32:691–697Google Scholar
  18. Yamamoto M, Usuda S, Tachikawa S, Maeno H (1982) Pharmacological studies on a new benzamide derivative, YM-09151-2, with potential neuroleptic properties. Neuropharmacology 21:945–951CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Roger D. Spealman
    • 1
  1. 1.Harvard Medical SchoolNew England Regional Primate Research CenterSouthboroughUSA

Personalised recommendations